SCHEMBL6847516

SCHEMBL6847516

Cc1cc2cc(-c3ccccc3)ccc2n1-c1cccnc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 1/20 0.45
CYP11B1 P15538 4/20 0.44
CYP11B2 P19099 4/20 0.44
CYP19A1 P11511 3/20 0.44
CYP17A1 P05093 2/20 0.44
ALOX12 P18054 1/20 0.44
GRM1 Q13255 2/20 0.43
ALDH1A1 P00352 3/20 0.41
KMT2A Q03164 3/20 0.41
MAPT P10636 2/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TCF4 P15884 1/20 0.40
CTNNB1 P35222 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ATM Q13315 1/20 0.40
NR3C1 P04150 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11988035 0.85 AVPR1A (0.45) ALDH1A1KMT2AKDM4EL3MBTL1NR3C1
SCHEMBL25919180 0.83 ALOX12 (0.47) MDM2ALOX12GRM1ALDH1A1KMT2A
SCHEMBL19041698 0.80 CYP11B2 (0.53) MDM2CYP11B1CYP11B2CYP19A1CYP17A1
SCHEMBL6655119 0.76 CYP11B2 (0.51) CYP11B1CYP11B2CYP19A1CYP17A1GRM1
SCHEMBL15159281 0.75 CYP1A2 (0.45) MDM2CYP11B1CYP11B2CYP19A1CYP17A1
SCHEMBL30118223 0.75 CYP1A2 (0.43) MDM2CYP11B1CYP11B2CYP19A1CYP17A1
SCHEMBL21068920 0.75 CYP1A2 (0.43) MDM2CYP11B1CYP11B2CYP19A1CYP17A1
SCHEMBL22515748 0.74 CYP11B2 (0.49) CYP11B1CYP11B2CYP19A1CYP17A1GRM1
SCHEMBL19041604 0.74 CYP1A2 (0.44) MDM2CYP11B1CYP11B2CYP19A1CYP17A1
SCHEMBL6844269 0.73 SCN2B (0.49) MDM2CYP11B2ALOX12GRM1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors BAYER PHARMACEUTICALS CORPORATION 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors CYP17A1, IDO1, CYP21A2 MDM2 542/4885CYP11B1 30/4885CYP11B2 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.